LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
The latest regulatory, legal, compliance, and technology news for labs and pathology practices.
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
Recall of Skippack Medical Lab SARS-CoV-2 Antigen Rapid Test the latest in string of recent Class I events.
Celltrion’s recall was labeled by the FDA as Class I, due to the kits possibly being distributed to non-CLIA certified users.
The OIG recently issued an Advisory Opinion approving a proposed arrangement involving the offering of free genetic tests.
False and fraudulent claims and billing were the theme in key enforcement actions relating to the health care industry announced last week.
The changes affect the Office of Product Evaluation and Quality’s Office of In Vitro Diagnostics and Radiological Health.
By the end of this month, G2 Intelligence’s website will have a new look and feel, plus simplified site navigation.
Recent report shows physician revenues, compensation, and productivity rose in the first quarter of 2022, but so did subsidies and expenses.
The IVDR will bring around 80 percent of in vitro diagnostic medical devices under the control of so-called Notified Bodies.
While the much-delayed IVDR will take effect at the end of the month, it will be rolled out gradually.
According to a recent survey of product security experts, despite many saying their companies are ready for hacks, data show otherwise.